Trial Profile
Relapse Rate and Predictive Factors in the Treatment of Hepatitis C in Common Clinical Practice.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms RE-CHUT
- Sponsors Merck Sharp & Dohme Corp.
- 06 Aug 2012 Actual patient number changed from 91 to 97 as reported by ClinicalTrials.gov.
- 06 Aug 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.